Clinical Trial Update: IL-1ra Dose-range Study for Moderate-to-severe TBI Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating dose-ranging of an IL-1 receptor antagonist for moderate-to-severe traumatic brain injury.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Anakinra (anakinra)

Snippet

Sponsor: Adel Helmy | Conditions: Traumatic Brain INjury | Phase 2 | Status: UNKNOWN